药物重新定位
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
蛋白酶
冠状病毒
2019年冠状病毒病(COVID-19)
化学
2019-20冠状病毒爆发
病毒学
药物发现
药品
重新调整用途
病毒复制
药物开发
抗病毒药物
药理学
计算生物学
病毒
传染病(医学专业)
酶
生物
医学
疾病
生物化学
病理
爆发
生态学
作者
Xiaojing Pang,Wei Xu,Yang Liu,Hua Li,Lixia Chen
标识
DOI:10.1016/j.ejmech.2023.115491
摘要
The novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide. The main protease (Mpro) of SARS-CoV-2 plays a central role in viral replication and transcription and represents an attractive drug target for fighting COVID-19. Many SARS-CoV-2 Mpro inhibitors have been reported, including covalent and noncovalent inhibitors. The SARS-CoV-2 Mpro inhibitor PF-07321332 (Nirmatrelvir) designed by Pfizer has been put on the market. This paper briefly introduces the structural characteristics of SARS-CoV-2 Mpro and summarizes the research progress of SARS-CoV-2 Mpro inhibitors from the aspects of drug repurposing and drug design. These information will provide a basis for the drug development of treating the infection of SARS-CoV-2 and even other coronaviruses in the future.
科研通智能强力驱动
Strongly Powered by AbleSci AI